A drug-eluting stent whose main body is made of a metal or a polymeric material, the surface of which is coated with a mixture including cilostazol and a bioabsorbable polymer, wherein the molecular weight of the bioabsorbable polymer is 40,000 to 600,000.

Various exemplary methods, systems, and devices for blood flow are provided. In general, an implant can be configured to be implanted in bone and to delay clotting of blood flowing from the bone. The implant can include an anti-coagulation agent to delay the clotting of the blood. The anti-coagulation agent can be a coating on the implant, can be natural to a material forming the implant, or can be impregnated into a material forming the implant. In an exemplary embodiment, the implant is implanted in a bone in a surgical procedure for securing a soft tissue to bone, such as a rotator cuff repair procedure or an anterior cruciate ligament (ACL) repair procedure.

There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.

A composition for wound healing, comprising an amount of a macrophage proresolving polarizer, wherein the amount is effective to promote wound healing. The composition includes wherein the macrophage proresolving polarizer is lipin-1. The composition includes wherein the composition includes one, two, or three of IL-4, apoptotic cells (ACs), and AC derived lipids. The composition includes wherein the macrophage proresolving polarizer is a lipin-1 transcriptional coregulatory activity promoter. The composition includes, wherein the lipin-1 transcriptional coregulatory activity promoter is an inhibitor of lipin-1 macrophage pro-inflammatory responses enzymatic activity. A method for promoting wound healing, comprising contacting a wound on a skin of a mammal with the composition. A kit comprising one or more containers including the composition in sterile packaging. A wound healing device comprising a substrate and an amount of an amount of a macrophage proresolving polarizer, wherein the amount is effective to promote wound healing.

Provided herein are human arterial endothelial cell-seeded polymeric vascular grafts suitable for replacing or bypassing natural blood vessels and exhibiting increased long term patency rates and reduced leukocyte adhesion relative to grafts comprising venous endothelial cells. Methods for generating the human arterial endothelial cell-seeded vascular grafts and therapeutic uses of the same are also described.

Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher.

There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.

The invention provides intravascular devices for treating certain medical conditions such as edema without causing thrombosis. The intravascular devices of the disclosure include non-thrombogenic surfaces that improve blood compatibility by reducing device-related thrombus formation and inflammatory reactions. The non-thrombogenic surfaces may include surface topographies (e.g., surface roughness) and modified chemistries (e.g., coatings and/or treatments), which prevent thrombosis by reducing local shear forces and inhibiting adhesion of blood clotting factors.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

The present disclosure is directed to a method of preparing an osteogenic bone graft. The method includes introducing an anticoagulant compound into a volume of cellular material including a mononuclear cell population from the intramedullary canal of a long bone; collecting an effluent including the volume of cellular material containing the anticoagulant compound at a collection point; separating a concentrated cell fraction from the effluent, the concentrated cell fraction including the mononuclear cell population and the anticoagulant compound; and preparing an osteogenic bone graft from the concentrated cell fraction.